Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway

Figure 2 Effects of carvedilol on cell cycle progression in human umbilical vascular endothelial cells. Cells were exposed to either control medium (containing 5% FBS) or medium containing the indicated concentrations of carvedilol and were treated as indicated in the Materials and Methods section. Representatives cytometric profiles (upper) and the percentage of cells at G0/G1, S and G2/M phases (%) (lower). The DNA content was determined by measuring the fluorescence intensity of incorporated propidium iodide.